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The gut microbiome and response 
to immune checkpoint inhibitors: preclinical 
and clinical strategies
Jun Gong1, Alexander Chehrazi‑Raffle2, Veronica Placencio‑Hickok1, Michelle Guan1, Andrew Hendifar1 
and Ravi Salgia3* 
Abstract 
There is growing interest in identifying predictive biomarkers for inhibitors of programmed cell death protein 1 recep‑
tor (PD‑1), programmed death ligand 1 (PD‑L1), and cytotoxic T‑lymphocyte associated protein 4 (CTLA‑4). Given the 
links between the stool microbiota, anticancer immunosurveillance, and general health, the composition of the gut 
microbiome has recently undergone investigation as a biomarker for immunotherapy. In this review, we highlight 
published results from preclinical and clinical studies to date supporting a relationship between the gut microbiome 
and antitumor efficacy of immune checkpoint inhibitors. Despite the promising and hypothesis‑generating findings 
that have been produced in this arena to date, there remain some inconsistencies amongst present data that may 
need to be resolved to contribute to further development. Among these, a better understanding of the immunomod‑
ulatory function of the microbiome, standardization in sampling, sequencing techniques, and data analysis, and 
ensuring uniformity across various aspects of study design are warranted in conducting future prospective studies 
seeking to validate the gut microbiome as a potential biomarker of response to checkpoint blockade.
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Introduction
There are currently several programmed cell death pro-
tein 1 receptor (PD-1) and programmed death ligand 
1 (PD-L1) inhibitors approved by the Food and Drug 
Administration (FDA) in the treatment of solid and 
hematologic cancers [1]. As the clinical development of 
PD-1/PD-L1 inhibitors continues to pick up considerable 
momentum, so does the search for predictive biomarkers 
for this class of immunotherapy. Among the earliest and 
most widely recognized predictive biomarkers is PD-L1 
expression though its absence in tumors certainly does 
not preclude response to PD-1/PD-L1 blockade [2].
Tumor mutational burden (TMB) has also been shown 
to predict benefit from immune checkpoint inhibitors 
across several tumor types due to generation of immu-
nogenic neoantigens arising from an increased burden of 
nonsynonymous mutations [3]. Tumors harboring muta-
tions in DNA mismatch repair genes resulting in micro-
satellite instability (MSI) or DNA polymerases (POLE) 
represent other phenotypes with high mutational load 
that can predict response to checkpoint blockade [4].
There is also growing interest in identifying the 
immune-active properties of the tumor microenviron-
ment (TME) that constitute an immunologically “hot” 
tumor in responders to PD-1/PD-L1 blockade, in con-
trast to the immunologically “cold” tumor [5, 6]. For 
example, the type, density, and location of tumor infil-
trating lymphocytes (TILs) are features that have been 
associated with response to checkpoint inhibition [7]. 
The Immunoscore represents a composite score incor-
porating such features of the infiltrating immune cell 
population and has been prospectively validated in 
colorectal cancer as a reliable prognostic indicator 
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with further investigations in other tumors as a pre-
dictor of response to checkpoint blockade [8]. Profil-
ing of the T-cell repertoire to assess for T-cell clonality 
may also serve as potential predictor of response to 
checkpoint inhibition [7]. Furthermore, assessment of 
a panel of markers associated with immune-sensitive 
or immune-resistant tumor phenotypes through gene 
expression profiling such as the Tumour Inflamma-
tion Signature or PanCancer IO 360 assay have shown 
promise in identifying candidates to PD-1/PD-L1 
blockade [7].
More recently, the gut microbiome has emerged as 
another potential predictor of response to immune 
checkpoint inhibitors. The microbiome and its asso-
ciation with general health has long been described, 
and the potential to confer health benefits on the 
host through direct and indirect manipulation of the 
intestinal microflora has been a subject of investiga-
tion for the past several decades [9]. Examples of such 
manipulation have included probiotics, which are live 
microorganisms or biotherapeutic products that when 
administered in adequate amounts confer a health 
benefit on the host, and prebiotics, which are sub-
strates such as carbohydrates or animal nutrition that 
are selectively used by host microorganisms to confer 
a potential health benefit. Clostridium butyricum, for 
instance, is a probiotic that has been shown to possess 
immunotherapeutic properties in cancer and gastro-
intestinal disorders [10, 11]. Prebiotics and synbiotics, 
which is a mixture of prebiotics and probiotics, have 
also demonstrated putative beneficial effects in the 
treatment of a multitude of other health conditions 
[12]. There are other microbiome studies investigat-
ing the relationship between the intestinal microbiota 
and efficacy of anticancer therapies, in general, in can-
cers of the lung and other organs, and the reader is 
referred to recent reviews [13–15]. In this review, we 
summarize the available evidence to date supporting 
the stool microbiota in shaping response to checkpoint 
blockade and their utility as a predictive biomarker for 
cancer immunotherapy. Beyond highlighting putative 
immunomodulatory mechanisms, we provide a phy-
logenetic classification of organisms associated with 
checkpoint inhibitor response and a succinct study-
by-study tabulation of findings to allow one to readily 
compare results across preclinical and clinical stud-
ies. We also provide a novel discussion of inconsist-
encies across preclinical and clinical studies that does 
not serve to discredit the biomarker potential of the 
gut microbiome for checkpoint blockade, but rather 
to highlight areas in need of further investigation to 
strengthen the development of this exciting concept in 
immunotherapy.
Preclinical studies
CpG‑oligonucleotides and anti‑interleukin antibodies
An eloquent study involving mice subcutaneously 
injected with melanoma (B16) and colon carcinoma 
(MC38) cells pretreated with an antibiotic cocktail was 
among the first to show the relationship between the 
stool microbiome and response to immunotherapy [16]. 
Antibiotic-treated and germ-free mice showed signifi-
cantly shorter survival and less tumor volume reduction 
with immunotherapy through injections of CpG-oli-
gonucleotides and anti-interleukin (IL)-10 antibodies, 
when compared to controls, and highlighted that com-
mensal gut microbiota primed tumor-infiltrating mye-
loid-derived cells through Toll-like receptor 4 (TLR4) 
activation and produce cytokines such as tumor necro-
sis factor (TNF) critical to antitumor efficacy (Table  1). 
Notably, administration of cultured Allstipes species 
(spp., A. shahii) or Lactobacillus spp. by gavage reconsti-
tuted or attenuated TNF-dependent tumor response to 
immunotherapy in antibiotic-treated mice, respectively 
(Table  1). Numbers of Lactobacillus spp. recovered as 
early as 1 week after stopping antibiotics, but recovery of 
Allstipes and Ruminococcus spp. was delayed, taking up 
to 4 weeks after stopping antibiotics.
Anti‑CTLA‑4 antibodies
In a subsequent study, tumor-bearing mice housed in 
germ-free conditions or treated with antibiotics experi-
enced comprised antitumor effects with anti-cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) therapy 
that were associated with significantly decreased effec-
tor CD4+ T-cells and tumor-infiltrating lymphocytes 
(TILs), when compared to controls [17]. Oral feeding of 
these mice with various Bacteroides spp. or Burkholderia 
spp. restored response to anti-CTLA-4 therapy associ-
ated with T-helper 1  (TH1) immune responses in tumor-
draining lymph nodes and maturation of intratumoral 
dendritic cells (DCs, Table 1). Fecal transplantation stud-
ies from metastatic melanoma patients to tumor-bearing, 
germ-free mice treated with anti-CTLA-4 therapy dem-
onstrated abundance of Bacteroides spp. that correlated 
with response. Intestinal reconstitution of antibiotic-
treated mice with Bacteroides fragilis and Burkholderia 
cepacia was also shown to reduce anti-CTLA-4-induced 
colitis.
Anti‑PD‑L1 antibodies
In mice subcutaneously injected with melanoma and 
bladder cancer, response to anti-PD-L1 therapy was 
significantly correlated with Bifidobacterium-treated 
mice (oral gavage) compared to non-Bifidobacterium-
treated mice that was associated with increases in 
interferon γ (IFN-γ)-producing tumor-antigen-specific 
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T-cells, major histocompatibility complex (MHC) Class 
II dendritic cells, and upregulation of gene transcripts 
involved in CD8+ T-cell activation and costimulation, 
DC maturation, antigen processing and cross presenta-
tion, chemokine-mediated immune cell recruitment to 
the TME, and type I interferon signaling [18]. Of note, 
Bifidobacterium was not detected in mesenteric lymph 
nodes, spleen, or tumor suggesting that systemic antitu-
mor immune responses occurred independently of bacte-
rial translocation.
In a separate melanoma-bearing mouse model, 
response to anti-PD-L1 therapy significantly correlated 
with fecal transplantations from patients abundant in 
Ruminococcaceae family and Faecalibacterium spp., 
while nonresponders to PD-L1 blockade had abundance 
in stool Bacteroidales order (Table  1). Mice responsive 
to checkpoint inhibition had significantly higher levels of 
CD8+ TILs and TME PD-L1 expression but lower levels 
of CD11b+CD11c+ suppressive myeloid cells compared 
to nonresponders, while increases in RORγT+ Th17 
tumor-infiltrating cells and regulatory CD4+ FoxP3+ 
T-cells and CD4+ IL-17+ T-cells were observed in non-
responders [19].
Anti‑PD‑1 antibodies
In mice established with sarcoma and melanoma, 2 weeks 
of broad-spectrum antibiotics and rearing in specific 
pathogen-free conditions adversely affected survival with 
PD-1 ± CTLA-4 blockade [20]. Reconstitution with com-
mensals such as A. muciniphila and E. hirae reversed 
resistance to PD-1 blockade in antibiotic-treated mice 
(Table  1). Interestingly, reconstitution with immune-
sensitizing microbes was associated with accumulation 
of memory CCR9-expressing Th1-associated chemokine 
receptor-expressing CD4+ T-cells in tumor beds, meta-
static lymph nodes, and draining lymph nodes 48 h after 
the first injection of anti-PD-1 antibody, formation of 
intratumoral granulomas, DC-induced IL-12 secretion, 
and increased CD4/Foxp3 ratios.
In a recent study involving fecal transplantation from 
melanoma patients who were responders and nonre-
sponders to anti-PD-1 therapy into melanoma-bearing 
germ-free mice, anti-PD-L1 therapy was effective in 
mice colonized with responder microbiota and ineffec-
tive in mice colonized with nonresponder microbiota 
[21]. Responder microbiota-reconstituted mice had sig-
nificantly higher numbers of SIY-specific  CD8+ T cells, 
but not  FoxP3+CD4+ regulatory T cells in the TME com-
pared to nonresponder-derived mice.
Clinical studies
Baseline gut microbiome diversity
Numerous clinical studies investigating the stool 
microbiome in patients treated with checkpoint inhib-
itors have since been conducted in an attempt to cor-
roborate findings demonstrated in preclinical models 
(Table  2). A prospective study collected buccal and 
fecal samples from 112 patients with metastatic mela-
noma prior to treatment with anti-PD-1 therapy [19]. 
Responders to anti-PD-1 therapy were significantly 
associated with higher diversity of gut microbiome 
and enriched with a unique stool bacterial composi-
tion compared to nonresponders; these findings were 
not observed in the oral microbiome (Table  2). Uni-
variate analyses identified that the strongest predic-
tors of response to anti-PD-1 therapy were alpha 
diversity [intermediate hazard ratio (HR) 3.60, 95% 
confidence interval (CI 1.02–12.74); abundance of Fae-
calibacterium genus (HR 2.92, 95% CI 1.08–7.89), and 
abundance of Bacteroidales order (HR 0.39, 95% CI 
0.15–1.03)] in the gut microbiome. Interestingly, a sig-
nificant positive correlation between tumor-infiltrat-
ing CD8+ TILs and higher levels of CD4+ and CD8+ 
T-cells in the systemic circulation with preserved 
cytokine response and abundance of the Faecalibacte-
rium genus, Ruminococcaceae family, and Clostridiales 
order in the gut was observed. Conversely, a nonsig-
nificant negative association between abundance of 
the Bacteroidales order and CD8+ TILs was observed. 
Higher abundance of Bacteroides order in the gut was 
associated with higher systemic levels of regulatory 
T-cells (Tregs) and myeloid derived suppressor cells 
(MDSCs) with a blunted cytokine response.
A recent investigation collected baseline stool sam-
ples from 42 patients with metastatic melanoma prior 
to anti-PD-1 therapy [21]. After removing operational 
taxonomic units (OTUs) found in < 10% of samples 
and integration of 16S ribosomal RNA gene sequenc-
ing, metagenomic shotgun sequencing, and quantita-
tive polymerase chain reaction (PCR), a selection of 
10 spp. was produced with differential abundance in 
responders and nonresponders to PD-L1 blockade 
(Table  2). Fecal transplantation from responding and 
nonresponding patients into melanoma-inoculated 
mice treated with anti-PD-L1 therapy largely recapitu-
lated outcomes and enrichment patterns seen in origi-
nal donors.
Effects of antibiotics
Clinical studies have also brought to attention the poten-
tial influence of antibiotics on outcomes in patients 
treated with checkpoint inhibitors. In one study of 
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249 patients with advanced non-small cell lung cancer 
(NSCLC, n = 140), renal cell carcinoma (RCC, n = 67), 
and urothelial carcinoma (n = 42) treated with PD-1/
PD-L1 blockade after ≥ 1 prior therapies, treatment with 
antibiotics (beta-lactam inhibitors, fluoroquinolones, 
or macrolides) 2 months before or 1 month after PD-1/
PD-L1 blockade was significantly associated with shorter 
progression-free survival (PFS) and overall survival (OS) 
[20]. Shotgun sequencing identified an overrepresenta-
tion of bacterial genera most notably including Akker-
mansia muciniphila in responders to PD-1 inhibition 
compared to nonresponders (Table  2, with or without 
antibiotics). Only Th1 and Tc1-cell reactivity against A. 
muciniphila and IFN-γ production above median were 
significantly associated with PFS in patients treated 
with PD-1 antibody. Oral gavage of sarcoma-carrying 
mice with stool samples from NSCLC patients who were 
responders and nonresponders recapitulated sensitivity 
and resistance to PD-1 blockade, respectively.
One retrospective study of patients with locally 
advanced or metastatic NSCLC investigated the out-
come of patients treated with nivolumab in the setting of 
antibiotic exposure [22]. Out of 15 patients treated with 
antibiotics, response and PFS was not significantly differ-
ent among those receiving nivolumab exposed and not 
exposed to antibiotics (Table  2). This study contradicts 
that of a larger retrospective study assessing the benefit 
of checkpoint blockade in advanced RCC and NSCLC 
patients exposed to antibiotics up to 30 or 60 days before 
the first dose of checkpoint inhibitor [23]. Increased rates 
of progressive disease (PD), shorter PFS, and shorter 
OS were observed in RCC patients exposed to antibiot-
ics up to 30 days, and shorter PFS and OS were observed 
in NSCLC patients exposed to antibiotics up to 30 days 
(Table 2). Results were largely similar on analysis of RCC 
patients exposed to antibiotics up to 60 days before first 
dose of checkpoint inhibitor. Although antibiotic use and 
tumor burden were independently associated with worse 
PFS but not OS on multivariate analysis in the RCC 
cohort, antibiotic use was independently associated with 
worsened OS in the NSCLC cohort.
Immune‑mediated colitis
Clinical studies have also recently begun to describe the 
influence of the microbiota in modulating a unique tox-
icity of checkpoint blockade—immune-mediated colitis. 
In a prospective cohort of metastatic melanoma patients 
treated with ipilimumab, serial fecal samples were col-
lected [24]. Relative reductions in gut microbiota were 
observed from baseline to time of onset of immune-
related colitis in various members of Firmicutes phylum. 
Interestingly, baseline enrichment with Firmicutes phy-
lum was significantly associated with developing colitis 
(p = 0.009) while significant enrichment in Bacteroidetes 
phylum was seen in those who did not develop colitis 
(p = 0.011). Patients who developed ipilimumab-induced 
colitis had significantly higher numbers of CD4+ T-cells 
but lower levels of IL-6, IL-8, and sCD25 at baseline com-
pared to those without colitis. Notably, the investigators 
showed that antibiotics before ipilimumab treatment did 
not influence baseline dominant microbiota and none of 
the potentially predictive taxa were associated with anti-
biotic use.
Baseline gut microbiota and metabolic signatures
A separate prospective cohort of 39 metastatic mela-
noma patients, of which 8% had used antibiotics prior to 
and/or during checkpoint blockade and 3% used probi-
otics, underwent metagenomic and metabolomic shot-
gun sequencing and provided a snapshot of baseline or 
pretreatment gut microbiota signatures associated with 
response to checkpoint inhibitors as well as significantly 
enriched and depleted metabolites involved in numerous 
metabolic pathways in responder metabolomes (Table 2) 
[25].
Discussion
The list of potential biomarkers that predict response, or 
lack of through primary, adaptive, and acquired resist-
ance, to checkpoint inhibitors is growing [26]. In the 
past 5  years, research into the association between the 
gut microbiome and response to PD-1/PD-L1/CTLA-4 
inhibitors has produced interesting findings on the topic 
(Tables  1, 2). The list of microbes that have been posi-
tively correlated with response to checkpoint blockade in 
the preclinical realm include: Bacteroides spp. and Burk-
holderia spp. (anti-CTLA-4), Bifidobacterium spp., Fae-
calibacterium spp., and more broadly, Ruminococcaceae 
family (anti-PD-L1), and Akkermansia muciniphila, Alis-
tipes indistinctus (of the Bacteroidales order), and Entero-
coccus hirae (anti-PD-1, Table 1). However, abundance of 
stool Bacteroidales order (includes Bacteroides spp.) has 
been associated with nonresponders to anti-PD-L1 ther-
apy in a separate preclinical study [19].
In clinical studies, findings that are both concordant 
and discordant to other clinical and preclinical studies 
on the gut microbiome have been produced (Table  2). 
Enrichment in the Firmicutes phylum (includes the 
Clostridiales order, e.g., Dorea formicigenerans, Eubac-
terium spp., and Veillonella parvula, Ruminococ-
caceae family, e.g., Ruminococcus spp., Blautia genus, 
Faecalibacterium genus, e.g., Faecalibacterium praus-
nitzii, and individual organisms Enterococcus faecium, 
Holdemania filiformis, Lactobacillus spp., and Strep-
tococcus parasanguinis), Bifidobacterium adolescentis, 
Bifidobacterium longum, Akkermansia muciniphila, 
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Collinsella aerofacien, Klebsiella pneumoniae, Alistipes 
spp. (of the Bacteroidales order), and Parabacteroides 
merdae/distasonis (of the Bacteroidales order) have been 
associated with response to PD-1 and CTLA-4 block-
ade in humans (Fig.  1) [19–21, 24, 25], while Bacteroi-
dales order (includes Bacteroides spp., e.g., Bacteroides 
thetaiotaomicron), Escherichia coli, and Anaerotruncus 
colihominis (of the Clostridiales order/Ruminococcaceae 
family), and Roseburia intestinalis (of the Clostridiales 
order) have been negatively associated with response 
to anti-PD-1 and anti-CTLA-4 therapy [19, 21, 24]. 
Notably, baseline enrichment in Bacteroidetes phylum 
(includes Bacteroides thetaiotamicron and Bacteroides 
caccae) has been associated with response to anti-PD-1 
and anti-CTLA-4 therapy in melanoma patients [25], 
which is in contrast to some preclinical and clinical evi-
dence described previously that support their abun-
dance as associated with lack of response. Furthermore, 
lack of response to anti-PD-1 or anti-CTLA-4 therapy 
in another melanoma cohort has been associated with 
baseline abundance in Ruminococcus obeum, which con-
tradicts other preclinical/clinical data supporting that gut 
enrichment with Ruminococcaceae family and Rumino-
coccus spp. positively correlate with response to check-
point inhibitors [21].
Where the utility of the stool microbiota falls along the 
spectrum of clinically-relevant biomarkers for check-
point blockade is unclear given the incongruent findings 
present in both published preclinical and clinical studies 
to date. Although interesting and thought-provoking, 
there remain a number of critical issues at hand that need 
to be addressed in order to establish the candidacy of the 
gut microbiome as a predictive biomarker for this prom-
ising class of immunotherapy.
Immunomodulatory mechanisms
It has long been implicated that the microbiome is 
involved in tumorigenesis as well as activation or sup-
pression of the immune system that can contribute to 
tumor control or escape [27, 28]. Early attempts in link-
ing the gut microbiome and anticancer immunosur-
veillance hypothesized that (1) microbial antigens may 
sufficiently stimulate antitumor immune activity through 
tumor antigenic mimicry or cross-reactivity, (2) microbes 
may provide a non-antigenic co-stimulus or secondary 
signal (or collection of signals) resulting in bystander 
activation of tumor associated antigen-specific T lym-
phocytes, and/or (3) microbial toxins and byproducts 
may directly or indirectly (through immunosurveillance) 
affect cancer cells [28]. Specific to the antitumor activity 
of immune checkpoint inhibitors, a growing body of evi-
dence now posits that the gut microbiota may enhance 
the function of DCs with more potent tumor antigen 
presentation and cytokine production, increase traf-
ficking of CD4+ memory T-cells from mesenteric and 
draining lymph nodes to the TME, decrease Tregs and 
MDSCs, and increase recruitment and activation of IFN-
γ-producing tumor-antigen-specific effector T-cells that 
Fig. 1 Phylogenetic tree of gut commensal bacteria associated with response to immune checkpoint inhibitors in both preclinical and clinical 
studies. Taxonomic classification is based on (from left to right) domain, phylum, order, family, genus, and species except for Terrabacteria 
(unranked). Figure created using the phylogenetic tree software by: [44]
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altogether contribute to the modulation of the antitumor 
immune response (Fig. 2) [29].
Evidence is also accumulating to support that immu-
noregulatory pathways that facilitate checkpoint inhibitor 
response may be commensal-specific [30]. In preclinical 
models, inoculation of mice with B. fragilis, A. muciniph-
ila, and E. hirae have been shown to induce  TH1 immune 
responses, promote maturation of DCs, and increase 
central memory CD4+ T-cells in mesenteric lymph 
nodes, tumor draining lymph nodes, and/or the TME 
in response to checkpoint inhibitors [17, 20]. Oral gav-
age of Bifidobacterium spp. in mice cotreated with anti-
PD-L1 therapy was shown to increase antigen-specific 
CD8+ TILs and MHC Class II DCs, while abundance of 
Clostridiales order, Ruminococcaceae family, and Faecal-
ibacterium genus was associated with increased CD8+ 
TILs and peripheral blood CD4+/CD8+ T-cells in 
human responders to PD-1 blockade [18, 19]. Abundance 
of A. muciniphila and E. hirae has been shown to be 
associated with secretion of cytokines by MCH Class II-
restricted CD4+ T-cells and DCs in the peripheral blood 
of human responders to PD-1 blockade (Fig. 2) [20].
Despite the initial insights into the immunomodula-
tory mechanisms of the stool microbiome, the exact 
mechanisms linking commensal bacterial species to the 
anticancer efficacy of checkpoint blockade in animal 
B. fragilis
Bifidobacterium 
Akkermansia 
muciniphila
E. hirae
Fig. 2 Proposed immunomodulatory mechanisms of commensal bacteria on anticancer efficacy of immune checkpoint inhibitors in animal 
models and patients. Oral gavage of B. fragilis in germ‑free mice has been shown to induce T helper 1  (TH1) immune responses in tumor‑draining 
lymph nodes and maturation of dendritic cells (DCs) in responders to cytotoxic T‑lymphocyte associated protein 4 (CTLA‑4) blockade. Oral gavage 
of Bifidobacterium spp. in mice was shown to increase accumulation of antigen‑specific  CD8+ tumor‑infiltrating lymphocytes (TILs) and major 
histocompatibility complex (MHC) Class II DCs in responders to programmed death ligand 1 (PD‑L1) blockade. Human responders to programmed 
cell death protein 1 receptor (PD‑1) blockade had significant positive correlations between CD8+ TILs or levels of CD4+ and CD8+ T‑cells in the 
peripheral blood and abundance of select members of the Clostridiales order, Ruminococcaceae family, and Faecalibacterium genus. Oral gavage 
of Akkermansia muciniphila and E. hirae was associated with increased central memory CD4+ T‑cells expressing the small intestine‑associated 
chemokine receptor CCR9 and/or the  TH1‑associated chemokine receptor CXCR3 in mesenteric and tumor draining lymph nodes as well as 
increased CD4/Foxp3 ratios in tumors of mice cotreated with anti‑PD‑1 therapy. In human peripheral blood, secretion of cytokines by CD4+ T‑cells 
including  TH1, Tc1, and interferon‑γ (IFN‑γ) and bone marrow‑derived DCs including IL‑12 were associated with response to PD‑1 blockade and 
reactivity against A. muciniphila and E. hirae (for Tc1)
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models and humans remain elusive. Our understanding 
of the impact of gut commensals on checkpoint inhibi-
tor response has benefited greatly from experiments 
performing immune profiling in subjects treated with 
immunotherapy and inoculated with specific bacteria 
[17–20]. Further insights into direct cause-effect rela-
tionships between checkpoint inhibitor response and 
stool microbiota have been afforded by fecal transplanta-
tion from human responders of immunotherapy to mice 
with in-depth characterization of immune responses 
[19–21]. However, these studies did not further identify 
the specific bacteria whose abundance was associated 
with immune responses; in recognition that fecal trans-
plantation from human responders can contain a diver-
sity of microbials and that mechanisms of checkpoint 
inhibitor response can be commensal-specific, broader 
investigation involving inoculation with single-lineage 
bacteria and immune profiling in responders would be 
prudent in our understanding of gut microbiome-facili-
tated response to immunotherapy.
An overarching question in this area is whether the 
abundance of stool bacteria associated with response to 
checkpoint blockade is simply a reflection of the pres-
ence of health-associated bacteria that are of usual higher 
quantities in healthier individuals with more robust 
and functional immune systems or is it through mecha-
nisms of the bacteria themselves that determine the 
host immune system’s capability to engage in antitumor 
responses [30]. On this latter note, it should also be asked 
whether the antitumor immune response is dependent 
solely on bacterial properties and their direct interac-
tions with the immune checkpoint inhibitors or through 
interactions involving the host-bacterial ecosystem and 
immunomodulatory cells [31]. Another research strategy 
to improve our understanding in this arena could entail 
investigating the magnitude by which gut commensals 
themselves stimulate innate and adaptive antitumor 
immune responses; these analyses have been initially 
presented in several studies [17, 18, 20]. Future study in 
controlled experiments evaluating immune profiles from 
inoculation of stool microbiota with and without check-
point inhibitors could provide further understanding of 
(1) whether immune response pathways elicited by com-
mensals are distinct from those generated by checkpoint 
blockade in altogether providing synergistic antitumor 
activity or (2) whether checkpoint blockade elicits anti-
tumor responses that overlap the same immune response 
pathways activated in recognition of bacterial antigens 
and byproducts. Additionally, greater understanding of 
underlying mechanisms may be afforded in research on 
the contribution of the microbiome to therapy-induced 
anticancer immune responses across other treat-
ment modalities beyond checkpoint inhibition such as 
chemotherapy, radiation therapy, hematopoietic stem cell 
transplantation, and other forms of immunotherapy [32, 
33].
Furthermore, metabolomics analysis has recently iden-
tified significant differences in 83 gut metabolites at base-
line in responders to anti-PD-1 and anti-CTLA-4 therapy 
compared to nonresponders with metastatic melanoma 
[25]. In essence, bacterial metabolites and byproducts of 
metabolic pathways involved in amino acid metabolism, 
lipid metabolism, nucleotide metabolism, and carbohy-
drate metabolism may also affect response to checkpoint 
blockade. As the putative mechanisms by which com-
mensal bacteria facilitate response to immunotherapy 
increases in complexity, further understanding of the 
relationships between the gut microbiome and the anti-
tumor immune response is critical in predicting success 
to checkpoint blockade.
Translation from preclinical to clinical settings
As stated previously, several inconsistencies in the gut 
microbiome composition have been produced in recent 
preclinical and clinical studies focused on investigating 
the relationship between stool microbiota and response 
to checkpoint inhibition (Tables  1, 2). Beyond associa-
tions between specific commensals and response (or lack 
of ) to checkpoint blockade, increased representation of 
baseline Bacteroidetes phylum (includes Bacteroides fra-
gilis) in melanoma patients and intestinal reconstitution 
with Burkholderia cepacia in antibiotic-treated, tumor-
bearing mice have been shown to reduce anti-CTLA-
4-induced colitis potentially by limiting inflammation 
through stimulation of Treg differentiation [17, 24, 34]. 
This is in contrast to studies showing an association with 
colonization by Bacteroides spp. and ulcerative colitis 
and Crohn’s disease in mice models and humans [35–
38]. Moreover, antibiotic use has been correlated with 
poorer outcome in tumor-carrying mice and metastatic 
RCC and NSCLC patients treated with anti-PD-1 and 
anti-CTLA-4 antibodies [17, 20, 23]. However, in 1 pro-
spective cohort of metastatic melanoma patients treated 
with ipilimumab and 1 retrospective cohort of advanced 
NSCLC patients treated with nivolumab, antibiotic use 
had no impact on response to checkpoint blockade or 
association on potentially predictive taxa [22, 24]. Lastly, 
a higher diversity of the gut microbiome in respond-
ing patients with melanoma to anti-PD-1 therapy was 
observed compared to nonresponders [19]. However, a 
separate melanoma cohort identified that there were no 
significant differences in the level of gut microbial diver-
sity between responders and nonresponders to anti-PD-1 
and anti-CTLA-4 therapy [25].
These inconsistencies across preclinical and clinical 
studies highlight several important points that need to be 
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considered in development of future research in this area. 
Firstly, caution should be taken in extrapolating data 
from mice studies into humans. The anatomical struc-
tures and intestinal wall linings have been shown to sig-
nificantly differ across human and mouse gastrointestinal 
tracts [39]. It has also been shown that 85% of the bac-
terial genera found in the mouse gut microbiome is not 
present in humans [40]. Furthermore, dynamic shifts in 
microbial species distribution can often occur due to host 
diet or lifestyle as well as interspecies competitive exclu-
sion [31, 41]. Sampling and sequencing technique of stool 
specimens is another factor that can introduce variabil-
ity in correlating the composition of the gut microbiome 
with checkpoint inhibitor response. Most human gut 
microbiome studies utilize stool samples, while mouse 
gut microbiome studies usually rely on cecal contents 
unless pellets are sampled in some longitudinal studies 
[39]. Historically, the standard choice for mouse studies 
has been mostly 16S rRNA sequencing whereas human 
microbiome studies have used both metagenomic and 
16S rRNA sequencing approaches [39]. Metagenomic 
shotgun sequencing has several potential advantages over 
16S rRNA sequencing as it can eliminate PCR bias seen 
with taxa that are over- or underrepresented depending 
on the choice of primers and 16S rRNA variable region to 
be amplified, improve gut microbiome taxonomic reso-
lution at the species level given that bacteria belonging 
to the same genus can have different phenotypes or host 
effects, and provide information on metabolic pathways 
of the microbiome [25]. Nevertheless, variability can exist 
in either strategy due to differences in collection, storage, 
and processing of stool samples, extraction protocols for 
nucleic acids, and approaches used in data analysis [30].
A third consideration encompasses study design, 
which has general applicability across models despite 
its particular relevance to non-preclinical studies. Dif-
ferences in study design including retrospective vs. pro-
spective design, sample size, experimental subject and 
tumor heterogeneity, and checkpoint inhibitor such as 
anti-CTLA-4 vs. anti-PD-1/PD-L1 can certainly account 
for the variability in findings across microbiome studies 
in animals and humans [31]. Differences in frequency 
of sampling can also affect the accuracy to describe 
variations in taxome distribution over time given that 
although the individual gut microbiome can remain sta-
ble for long durations of time, changes in composition 
of the microbiome can rapidly occur due to antibiotics, 
dietary, and environmental changes [25]. In the largest 
cohort to date investigating the impact of antibiotics on 
the gut microbiota and response to checkpoint blockade, 
factors with potential impact on the microbiota composi-
tion such as diet, country of origin, and use of other med-
ications were not taken into account [23]. It should be 
pointed out that although a detrimental effect of antibiot-
ics on response to checkpoint blockade was identified in 
this study, the authors are unclear whether this reflects 
a general prognostic association or a causative link with 
resistance to checkpoint inhibition [23].
Future directions for clinical studies
The gold standard in designing the ideal investigation 
of the gut microbiome composition as a predictor of 
response to checkpoint blockade would involve taking 
into consideration all of the above points and incorporat-
ing them into a study of large sample size and prospective 
design. This is easier said than done, but to ensure our 
success in conducting high-quality research with minimal 
bias and confounding factors in this arena, future efforts 
can implement several key study parameters. Techniques 
in sampling and sequencing should be standardized; in 
the case of 16S rRNA sequencing, it will be important 
to minimize variations in the many proposed algorithms 
for clustering of genetic sequences into OTUs to meas-
ure microbiome diversity that have been found to have a 
negative influence on downstream analyses [31]. Further-
more, serial and longitudinal sampling will be of value 
to assess changes in an individual’s gut microbiome over 
time in relation to checkpoint inhibitor response [25, 42]. 
To the best of our ability, controlling for or taking into 
account baseline differences in an individual’s micro-
biome profile across patient demographics such as sex, 
age, race, comorbidities, medications including antibiot-
ics and probiotics, diet and lifestyle, and environment/
geographic location will add greatly to the development 
of a more standard measurement for future microbiome 
investigations [31].
It is increasingly understood that the diversity of the gut 
microbiome may include some bacterial species that are 
immunosuppressive while others that are immune-stim-
ulatory [43]. Rather than risk the likelihood of underesti-
mating the total number of bacteria showing differential 
abundance in responders compared to nonresponders of 
checkpoint inhibition (a problem often encountered in 
16S rRNA sequencing given that the analysis is limited 
by the number of samples above the detection threshold), 
representing the data in aggregate through construction 
of a ratio comprised of the total number of “beneficial” 
and “nonbeneficial” OTUs has demonstrated feasibility 
in producing a composite commensal microbiota score 
that is predictive of benefit to checkpoint blockade [21]. 
Furthermore, improvements in the isolation of cultivable 
bacteria and derivation of individual clones with imple-
mentation of whole-genome sequencing may represent 
future steps in our ability to study the composition of the 
gut microbiome [30]. In developing the ideal biomarker 
for checkpoint inhibitors beyond the gut microbiome, 
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future investigations may expand their attention beyond 
bacteria to the broader ecological community such as 
viruses and fungi; integration of the microbiome with 
metabolomics, proteomics, and genomics may provide 
an even more comprehensive prognostic and predictive 
biomarker [30, 42].
Lastly, with better uniformity across sampling tech-
niques, data analysis, and study design and a greater 
understanding of the immunomodulatory mechanisms 
of the microbiome, we will be primed to investigate 
strategies to modify the gut microbiome and potentially 
improve cancer outcomes. There are numerous ongoing 
clinical studies and prospective trials investigating the 
role of intestinal commensals and their effect on antican-
cer therapies (Table 3). Ideally, these studies will provide 
some clarity to many of the questions that have emerged 
on manipulation of the stool microbiome and cancer 
immunotherapy. In line with the concept of precision 
oncology, a future goal would involve manipulation of 
an individual’s microbiome through potential strategies 
including fecal microbial transplantation, provision of 
single bacterial species or a cocktail of beneficial organ-
isms, dietary interventions, antibiotics, and/or probiotics 
to enhance the effect of anticancer therapies [30].
Conclusion
Preclinical and clinical evidence is accumulating to sup-
port an association between the gut microbiome com-
position and antitumor efficacy of immune checkpoint 
inhibitors. However, to further its advancement as a 
potential biomarker for immunotherapy, there are sev-
eral inconsistencies amongst present data that should 
be addressed. A greater understanding of the immu-
nomodulatory mechanisms of the microbiome, stand-
ardization of sampling, sequencing techniques, and data 
analysis, and ensuring uniformity in study design are 
key considerations that may need to be incorporated 
into future investigations. Ultimately, validation of find-
ings from existing preclinical and clinical data in subse-
quent studies of large sample size and prospective design 
is warranted to further develop the stool microbiota as a 
biomarker for checkpoint blockade.
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